Breaking News
March 22, 2019 - Servier collaborates with Harvard researchers to fight metabolic diseases
March 22, 2019 - National Eating Disorders Association
March 22, 2019 - Pumping up red blood cell production
March 22, 2019 - Excessive phosphate fertilizer may hurt plants by altering microbial composition in soil
March 22, 2019 - Medical marijuana laws could be improving older Americans’ health, study suggests
March 22, 2019 - Study indicates the benefits of stopping aspirin in heart attack patients
March 22, 2019 - Deep brain stimulation offers significant relief for patients with treatment-resistant depression
March 22, 2019 - Mental health problems in young adults on the rise
March 22, 2019 - Innovative membrane offers a viable solution for periodontitis
March 22, 2019 - The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
March 22, 2019 - insulin therapy: MedlinePlus Medical Encyclopedia
March 22, 2019 - Guidelines on the use of genetic testing in psychiatry
March 22, 2019 - Aspiring Doctors Seek Advanced Training In Addiction Medicine
March 22, 2019 - A change in focus could enable the development of new treatments for Alzheimer’s disease
March 22, 2019 - A new way to visualize the immune cell “landscape” of bowel cancer tumors
March 22, 2019 - Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia
March 22, 2019 - Ludwig scientists to share advances in cancer research at AACR Annual Meeting 2019
March 22, 2019 - Less invasive valve replacement can be safe and effective alternative for healthier patients
March 22, 2019 - Aphasia research reveals new, complex interactions between thought and language
March 22, 2019 - Artificial neural networks can predict how different areas in the brain respond to words
March 22, 2019 - Age-related changes to gut microbiome have adverse impact on vascular health, study shows
March 22, 2019 - Isolated seniors chat online to prevent cognitive decline
March 22, 2019 - Naltrexone implant more effective in reducing relapses in HIV patients with opioid addiction
March 22, 2019 - The Brain Institute wins $7.04 million grant to investigate ‘neurophilosphy of free will’
March 22, 2019 - Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
March 22, 2019 - Eruptive xanthomatosis
March 22, 2019 - Cause of vascular disease in kidney failure reversed in animal model
March 22, 2019 - Researchers discover possible new therapeutic strategy for pancreatic cancer
March 22, 2019 - Ebola spreads to second largest city in DRC
March 22, 2019 - Perivascular spaces contribute to worse cognitive health in older adults
March 22, 2019 - Adolescent daily users more likely to obtain electronic cigarettes from commercial sources
March 22, 2019 - FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
March 22, 2019 - Diabetes myths and facts: MedlinePlus Medical Encyclopedia
March 22, 2019 - TGen and ABL pursue global rollout of advanced TB test
March 22, 2019 - Traffic light labels influence people to choose healthier and more sustainable meals
March 22, 2019 - Alzheimer’s patients using antiepileptic drugs have twice the risk of pneumonia, study shows
March 22, 2019 - Skin diseases may be more prevalent than previously thought
March 22, 2019 - Overall rates of death from breast cancer are falling across the EU
March 22, 2019 - Novel plasmid could hold key to control of mosquito-borne illness
March 22, 2019 - Female Emergency Physicians Paid Less Than Males
March 22, 2019 - Estimated average glucose (eAG): MedlinePlus Medical Encyclopedia
March 22, 2019 - Experimental drug could be new option for type 2 diabetes
March 22, 2019 - Five Things To Know About The Electronic Health Records Mess
March 22, 2019 - TMJ disorders could be treated with tissue-engineered implants after successful animal study
March 22, 2019 - Team-based approach is key to successful care of pregnant women with heart failure
March 22, 2019 - Study identifies gene variant associated with accelerated cellular aging
March 21, 2019 - Salk scientists show how background noise from neurons can interrupt focused attention
March 21, 2019 - New class of drugs could help treat patients diagnosed with ovarian cancer
March 21, 2019 - Tecentriq Approved for Small Cell Lung Cancer
March 21, 2019 - Adipocyte glucocorticoid receptors play a role in developing steroid diabetes
March 21, 2019 - Climate change can affect nutrient content of crops, harming human health
March 21, 2019 - Podcast: KHN’s ‘What The Health’ Surprise! Fixing Surprise Medical Bills Is Harder Than it Looks
March 21, 2019 - Chemistry researchers patent new method for making anti-leukemia compounds
March 21, 2019 - UIC scientists identify hidden proteins in bacteria
March 21, 2019 - New Australian drug trial achieves remarkable results in patients with acute myeloid leukemia
March 21, 2019 - Females live longer when they have help raising offspring
March 21, 2019 - How did orthodontists sell orthodontics?
March 21, 2019 - In the Spotlight: From dietitian to physician assistant student
March 21, 2019 - The CRISPR Revolution: What You Need to Know
March 21, 2019 - FDA Chief Calls For Stricter Scrutiny Of Electronic Health Records
March 21, 2019 - Combined glucocorticoid and antioxidant therapy could benefit premature babies
March 21, 2019 - Low levels of certain eye proteins could serve as predictor for Alzheimer’s
March 21, 2019 - Post-traumatic holocaust survivors transmit negative views on aging to offspring
March 21, 2019 - City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma
March 21, 2019 - New video game-led training device helps stroke survivors regain arm mobility
March 21, 2019 - Compounds in coffee could slow prostate cancer growth
March 21, 2019 - New mobile DNA element in Wolbachia may contribute to improved disease control strategies
March 21, 2019 - Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
March 21, 2019 - More than one-third of patients risk major bleeding by doubling up on blood thinners
March 21, 2019 - A skeptical look at popular diets: Thumbs up for Mediterranean
March 21, 2019 - PTSD After Cardiac Arrest Predicts More Heart Trouble
March 21, 2019 - Role of immunological imprinting in elicitation of new antibodies
March 21, 2019 - Breast cancer relapse predictor tool may soon be a reality
March 21, 2019 - New computer program developed by TGen lights up cancer-causing genetic mutations
March 21, 2019 - FDA warns two breast implant makers for failure to comply with post-approval study requirements
March 21, 2019 - Butler Hospital receives COBRE grant to enhance research on neuropsychiatric illnesses
March 21, 2019 - Majority of osteoporosis clinical practice guidelines ignore patients’ voices
March 21, 2019 - Generic messages don’t help patients to lose weight
March 21, 2019 - Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 21, 2019 - Two-drug combos using popular calcium channel blocker show superiority in lowering BP
New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

image_pdfDownload PDFimage_print

A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new antibiotic effectively treats uncomplicated urogenital and rectal gonorrhea infections in a single oral dose. Results are published in the November 8, 2018, issue of the New England Journal of Medicine.

“According to the Centers for Disease Control and Prevention, the incidence of gonorrhea in the US increased by 67% from 2013 to 2017,” notes Dr. Taylor. “The bacteria causing gonorrhea, Neisseria gonorrhoeae, has developed resistance to every class of antibiotic currently recommended for treatment, and reports of multidrug-resistant N. gonorrhoeae necessitate the urgent development of new antimicrobial agents.”

The researchers conducted a randomized, open-label phase 2 clinical trial to determine the safety and effectiveness of the investigational drug, zoliflodacin, in treating uncomplicated gonorrhea infections. Zoliflodacin, which has been fast-tracked by the FDA, works differently from the antibiotics currently available to treat gonorrhea. It inhibits DNA biosynthesis in a new way, impeding bacterial growth. Entasis Therapeutics in Waltham, MA developed zoliflodacin.With a goal of 144 participants with gonorrhea, a total of 179 participants were enrolled at sexual health clinics in New Orleans, Seattle, Indianapolis, Birmingham and Durham, North Carolina from November 2014 through December 2015. The men and non-pregnant women, 18 – 55 years old, were eligible if they had signs and symptoms of urogenital gonorrhea, untreated urogenital gonorrhea or sexual contact in the preceding 14 days with a person who had gonorrhea. Urethral, cervical, pharyngeal and rectal swabs were taken at enrollment. Thirty-eight participants were excluded due to negative cultures. Participants were randomly assigned to receive a single, oral dose of either 2 or 3 grams of zoliflodacin or a single injected dose of 500 mg of ceftriaxone, one of the two drugs currently used to treat gonorrhea.

The microbiologic intention-to-treat (micro-ITT) group (141 participants) included all participants with gonorrhea at urethral or cervical sites. The per-protocol group included the participants in the micro-ITT group who met all inclusion criteria, did not have another infection other than chlamydia or bacterial vaginosis, did not receive any other systemic antibiotic before test of cure and returned for a test-of-cure visit within a six-day window.

The primary measure of efficacy was the proportion of participants with urogenital infections who were cured. The secondary measure of effectiveness was the number of participants whose pharyngeal and rectal infections were cured. The primary safety outcome measure was the proportion of participants reporting adverse events.

Treatment with 2 or 3 g of zoliflodacin resulted in a 96% cure rate in those with urogenital infections in the micro-ITT group, while the cure rate for those treated with ceftriaxone was 100%. In the per-protocol group, 98% of the participants who took the 2-gram dose of zoliflodacin and 100% of those who received the 3-gram dose, as well as all of the participants in the ceftriaxone group, were cured. All of those with rectal infections who were treated regardless of dose or medication were cured. Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, respectively.

A total of 21 adverse events were associated with zoliflodacin, mostly gastrointestinal. In the ceftriaxone group, 23 adverse events were reported.

“Ceftriaxone is one of two drugs used as the current standard of care to treat uncomplicated gonorrhea,” adds Taylor. “A cephalosporin, it is the last class of antibiotics we have to treat gonorrhea. While it has worked well, we are starting to see resistance to it, too. Since there is no vaccine to prevent gonorrhea, and the possibility of untreatable gonorrhea is looming larger, it is imperative that we develop new drugs to treat it. Our promising early results suggest that zoliflodacin could be one of them.”

According to the CDC, gonorrhea is the second most commonly reported notifiable disease in the United States. In 2017, a total of 555,608 cases of gonorrhea were reported in the United States. Louisiana ranks second in the nation with 257 cases per 100,000 people reported last year. Infections due to Neisseria gonorrhoeae are a major cause of pelvic inflammatory disease (PID) in the United States. PID can lead to serious outcomes in women, such as tubal infertility, ectopic pregnancy, and chronic pelvic pain. In addition, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.

Source:

https://www.lsuhsc.edu/newsroom/Study%20Finds%20New%20Single-Dose%20Antibiotic%20Safe%20and%20Effective%20for%20Uncomplicated%20Gonorrhea.html

Tagged with:

About author

Related Articles